KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$2.0 billion.

  • Teva Pharmaceutical Industries' Net Income towards Common Stockholders rose 160.11% to $428.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.0 million, marking a year-over-year increase of 116.01%. This contributed to the annual value of -$2.0 billion for FY2024, which is 59.01% down from last year.
  • Teva Pharmaceutical Industries' Net Income towards Common Stockholders amounted to -$2.0 billion in FY2024, which was down 59.01% from -$1.2 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' 5-year Net Income towards Common Stockholders high stood at -$519.0 million for FY2021, and its period low was -$4.0 billion during FY2020.
  • Its 3-year average for Net Income towards Common Stockholders is -$2.2 billion, with a median of -$2.0 billion in 2024.
  • In the last 5 years, Teva Pharmaceutical Industries' Net Income towards Common Stockholders skyrocketed by 86.99% in 2021 and then crashed by 538.54% in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' Net Income towards Common Stockholders (Yearly) stood at -$4.0 billion in 2020, then soared by 86.99% to -$519.0 million in 2021, then crashed by 538.54% to -$3.3 billion in 2022, then soared by 62.67% to -$1.2 billion in 2023, then tumbled by 59.01% to -$2.0 billion in 2024.